Metis TechBio Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	105	1.48	9.34
Revenue Growth (YoY)	6985.02%	-84.13%	-
Cost of Revenue	1.91	0.66	3.75
Gross Profit	103.09	0.82	5.59
Selling, General & Admin	218.71	104.39	109.15
Research & Development	269.81	274	290.46
Other Operating Expenses	-10.96	-6.38	-1.36
Operating Expenses	477.55	372.01	398.26
Operating Income	-374.47	-371.19	-392.67
Interest Expense	-31.81	-168.5	-70.2
Interest & Investment Income	22.17	23.79	12.01
Currency Exchange Gain (Loss)	-11.25	12	-7.85
Other Non Operating Income (Expenses)	-0.26	-0.13	-0.32
EBT Excluding Unusual Items	-395.61	-504.03	-459.04
Gain (Loss) on Sale of Investments	4.63	6.85	0.1
Gain (Loss) on Sale of Assets	-0	-0.61	-0.5
Asset Writedown	-0.73	-1.4	-61.94
Other Unusual Items	-	-	-60.55
Pretax Income	-391.71	-499.19	-581.93
Income Tax Expense	0.12	0.01	0
Net Income	-391.84	-499.2	-581.93
Net Income to Common	-391.84	-499.2	-581.93
Shares Outstanding (Basic)	94	-	-
Shares Outstanding (Diluted)	94	-	-
EPS (Basic)	-4.16	-	-
EPS (Diluted)	-4.16	-	-
Free Cash Flow	-140.25	-242.55	-241.92
Free Cash Flow Per Share	-1.49	-	-
Gross Margin	98.18%	55.53%	59.81%
Operating Margin	-356.63%	-25046.49%	-4205.10%
Profit Margin	-373.18%	-33684.08%	-6231.83%
Free Cash Flow Margin	-133.57%	-16366.46%	-2590.73%
EBITDA	-344.88	-338.04	-364.39
D&A For EBITDA	29.59	33.15	28.28
EBIT	-374.47	-371.19	-392.67

Source: S&P Global Market Intelligence. Standard template. Financial Sources.